THE PUBLIC-PRIVATE Partnership Center has issued the invitation to bid for the second phase of the Vaccine Self-Sufficiency Project, only the third among the identified PPP projects to be placed on the auction block since the PPP program’s launch last year.
The notice, posted on the PPP Center’s website Thursday, was targeted at entities interested in providing consultancy services for the conduct of a feasibility study for the proposed Vaccine Self-Sufficiency Project Phase II.
The approved budget for these consultancy services has been placed at P5 million.
Interested parties have to submit their eligibility documents and pay a non-refundable fee of P5,000 on or before 10 a.m. of Sept. 16 to move on to the pre-qualification stage.
The PPP Center will then come up with a short list of not more than five prospective bidders for the project.
They will be identified based on the following criteria: applicable experience of the consultant or members of the consultancy team, qualifications and credentials of the principal and key staff, and current workload capa-city.
The potential bidders also have to be Filipino firms, or having at least 60 percent of outstanding capital stock belonging to Philippine citizens.
Foreigners can join the bidder’s staff, subject to the provisions of the implementing rules and regulations of RA 9184, or the Government Procurement Reform Act.
Only those parties on the short list can avail themselves of the bid documents upon payment of a non-refundable P30,000 fee.
Upon award, the contract should be completed within two months.
The Department of Health’s Vaccine Self-Sufficiency Project is seen reducing the overall cost of annual vaccine procurement by at least 20-30 percent, equivalent to savings of P240 million to P360 million.
The DOH allots P1.2 billion a year to purchase vaccines.
The project will also pave the way for the establishment of facilities for the local formulation, packaging, and labeling of pentavalent vaccine (Diptheria, Pertussis, Tetanus, Hepatitis B, Haemophylus Influenza B), Tetanus Toxoid, and single-dose Hepatitis B.